DUBLIN – Genomics plc raised £25 million (US$32.5 million) in a series B round, led by Vertex Pharmaceuticals Inc., which also signed up for a three- to five-year collaboration in which the Oxford, U.K.-based data science firm will hunt for new drug targets and seek new disease insights by analyzing extensive repositories of human genetic data that are linked to phenotypes and clinical outcomes.